BioSpace News Archive

Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, announced that Benny Sorensen, M.D., Ph.D. resigned from his position as a Senior Vice President of Strategic Projects to become CEO of a privately held biotech company, Hemab Therapeutics, focused on rare bleeding and thrombosis disorders.

Rising incidences of HIV, ongoing research activities, and private and government investments on healthcare sector.

Brooklyn ImmunoTherapeutics LLC announced that on June 21 2021, Sandra M. Gurrola was granted a restricted stock unit grant covering 35,000 shares of Brooklyn’s common stock, and that on June 28, 2021, Kevin A. D’Amour was granted a non-qualified stock option covering 140,580 shares of Brooklyn’s common stock and a restricted stock unit covering 70,290 shares of Brooklyn’s common stock.

Mesa Laboratories, Inc. announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock.

Growing demand for biocompatible 3D printing materials in several medical applications is driving the market revenue growth.

The global wound irrigation system market is expected to reach US$ 310.43 Mn in 2027 from US$ 238.43 Mn in 2018.

Integrity Implants Inc., a privately held medical device company focused on Adaptive Geometry™ technology designed to enable MIS spine surgery, and Fusion Robotics, LLC, a privately held medical technology company focused on efficient and cost-effective navigation and robotic targeting solutions for spine surgery, today announced that they have consummated a merger combining the two companies.

Sorrento Therapeutics, Inc. (NASDAQ: SRNE, “Sorrento”) announced today that the company has received FDA clearance to proceed with a Phase 2 clinical study of RTX for treating moderate-to-severe osteoarthritis of the knee pain (OAK).

Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced the closing of its upsized underwritten public offering of 5,468,250 shares of its common stock at a public offering price of $47.00 per share,

Zion Market Research has published a new report titled “Dental Imaging System Market by Dental Imaging Device Type (2D and 3D Imaging System), Product Type (Intraoral and Extra Oral Radiography System) and by End Users (Dental Clinics & Laboratories, Hospitals, and Dental Institutes): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2018 - 2024”.